IP Library Granted Patent US 9,872,937
Granted Patent B2
US 9,872,937 · App. 15/148,821 · Granted Jan 23, 2018

Compositions and methods for treating and preventing tissue injury and disease

Inventors: Dale R. Peterson (Carlsbad, CA); Ralph-Heiko Mattern (Ramona, CA); Cory Wilson-Wirth, I (San Diego, CA); Kevin L. Ohashi (Jamaica Plain, MA)
Assignee: Microvascular Tissues, Inc.
A61L27/54A61J1/06A61K9/0019A61K9/19A61K35/28A61L27/3625C12N5/00A61J1/035A61L2300/41A61L2300/412A61L2300/64
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,872,937
App. No.
15/148,821
Granted
Jan 23, 2018
Kind
B2
Abstract

The present invention provides novel compositions comprising multipotent cells or microvascular tissue, wherein the cells or tissue has been sterilized and/or treated to inactivated viruses, and related methods of using these compositions to treat or prevent tissue injury or disease in an allogeneic subject.

Claims (14)

1. A composition comprising processed microvascular tissue, wherein the processed microvascular tissue comprises isolated, uncultured multipotent cells wherein the composition is sterilized by irradiation, and wherein the composition has one or more of angiogenic activity or anti-inflammatory activity greater than saline alone, and wherein less than or equal to 50% of the cells present in the composition are viable.

2. The composition of claim 1 , wherein the processed microvascular tissue comprises cell membrane, cellular components, or a combination thereof and wherein the cell membrane or cellular component is derived from multipotent cells or from microvascular tissue.

3. The composition of claim 1 , wherein less than or equal to 10% of the cells present in the composition are viable.

4. The composition of claim 3 , wherein substantially none of the cells present in the composition are viable.

5. The composition of claim 1 , wherein at least 1% of the cells exclude trypan blue.

6. The composition of claim 1 , wherein the composition retains measurable angiogenic or anti-inflammatory activity when stored at approximately room temperature for at least one month.

7. The composition of claim 1 , wherein the composition is dried, lyophilized, or cryopreserved.

8. The composition of claim 1 , wherein the composition further comprises an excipient.

9. The composition of claim 1 , wherein the composition further comprises an implantable scaffold or matrix.

10. The composition of claim 1 , wherein the composition is formulated for intravenous administration.

11. The composition of claim 1 , wherein the cells or tissue are obtained from a mammalian donor, optionally a human.

12. The composition of claim 1 , wherein the cells comprise stem cells or progenitor cells.

13. The composition of claim 1 , wherein the irradiation is at a dose greater than 0.5 Mrad.

14. The composition of claim 1 wherein the composition is treated to inactivate virus.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 11, 2017
From: PETERSON, DALE R.; MATTERN, RALPH-HEIKO; WILSON-WIRTH, COREY; OHASHI, KEVIN L.
To: MICROVASCULAR TISSUES, INC.
Reel/Frame 043841/0976 →
Continuity (3)
Continuation 14429511
Provisional Application 61703203 · Sep 19, 2012
Related Publication 20160271187A1 · Sep 22, 2016